Montravers, Philippe http://orcid.org/0000-0002-3422-5705
,
Tubach, Florence
Lescot, Thomas
Veber, Benoit
Esposito-Farèse, Marina
Seguin, Philippe
Paugam, Catherine
Lepape, Alain
Meistelman, Claude
Cousson, Joel
Tesniere, Antoine
Plantefeve, Gaetan
Blasco, Gilles
Asehnoune, Karim
Jaber, Samir
Lasocki, Sigismond
Dupont, Herve
Funding for this research was provided by:
French Ministery of Health-Programme Hospitalier de Recherche Clinique 2009 (AOM-09024)
Article History
Received: 9 December 2017
Accepted: 5 February 2018
First Online: 26 February 2018
Compliance with ethical standards
:
: Dr. Montravers reports personal fees and non-financial support from Astellas, AstraZeneca, Basilea, Bayer, Cubist, Menarini, MSD, Parexel, Pfizer, Tetraphase and The Medicines Company unrelated to the submitted work. Dr. Lescot reports grants, personal fees and non-financial support from Baxter, personal fees and non-financial support from Fresenius and personal fees from MSD unrelated to the submitted work. Dr. Paugam reports personal fees from MSD, Astellas and Baxter-Gambro unrelated to the submitted work. Dr. Lepape reports personal fees from Biomerieux unrelated to the submitted work. Dr. Blasco reports personal fees and non-financial support from Baxter, Astellas, Pfizer, MSD and Gilead unrelated to the submitted work. Dr. Asehnoune reports personal fees from LFB, Fresenius and Baxter unrelated to the submitted work. Dr. Jaber reports personal fees from Drager, Hamilton, Maquet and Fisher-Paykel unrelated to the submitted work. Dr. Lasocki reports research grants from Vifor Pharma and grants from LFB and Astellas unrelated to the submitted work. Dr. Dupont reports personal fees from Astellas, Pfizer, Gilead, Astrazeneca, Novartis, Merck, Cubist and and Paratek unrelated to the submitted work. No other disclosures were reported.
Free to read: This content has been made available to all.